Heart Disease Trial, Recruiting NCT05960968 Sponsor: Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05960968
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have signed a consent form agreeing to take part in the study
  • People who have been admitted to hospital where the main reason for admission is a sudden worsening of heart failure, and where the treating doctor has prescribed a heart-related treatment such as a water tablet (diuretic), a blood vessel relaxant, a medication to support the heart's pumping, or a medical device
  • People who have been admitted to hospital for another reason, but where long-term heart failure is identified during that stay through tests, blood results, or scans, and where the treating doctor has prescribed a heart-related treatment such as those listed above during the hospital stay

Who may not be able to join:

  • People who have an active COVID-19 infection or a confirmed case of COVID-19 pneumonia at the time of the study
  • People who have an uncontrolled psychiatric condition or significant cognitive difficulties that would make it too hard to complete the study survey (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: PAOLA VARLETA, MD, Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular

Phone: +569 95390767

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fundacion de la Sociedad Chilena de Cardiologia y Cirugia Cardiovascular
Registry
ClinicalTrials.gov
Start date
11 August 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇱 Chile

Primary endpoints

The prevalence of HF phenotype( preserved, mildly reduced or reduced) by sex

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov